Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Regulation Business Practice, Digital Technologies

Imposter Twitter Account Loses Eli Lilly Billions

It’s chaos out there, folks.

Republican Kari Lake conceded in Arizona. Nestle tweeted, “We steal your water and sell it back to you lol.” Donald Trump tweeted that Obama was the best president of our lifetime. Apple was selling air atoms that would be required for you to enter Apple stores. Tesla tweeted “Our analysis engineers simulate hundreds of impact scenarios before ever killing a child in real life.”

And Eli Lilly tweeted that insulin was “now free.”

All of the accounts responsible for these tweets may have looked real enough at a glance, but they were imposters – the door opened by the $8 “Twitter Blue” subscription for a verification checkmark, which has granted trolls a relatively low-cost license to run wild. Ahead of Elon Musk’s reign, the blue checkmark was used to show that certain accounts, such as those used by celebrities or big brands, were authentic – though the process behind gaining verified status was somewhat obscure.

For Eli Lilly, someone’s $8 caused enormous damage – stock dropped 5 percent and billions were wiped off of the company’s value. The post was up for hours before Eli Lilly’s real account tweeted a response saying, “We apologize to those who have been served a misleading message from a fake Lilly account. Our official Twitter account is @LillyPad.”

For Twitter trolls, the fun had only just begun. Other imposter Lilly accounts were quick to appear. A new account @LillyPadCo with the verification checkmark tweeted to say, “We apologize to those who were have [Sic] been served a misleading message from a fake Lilly account about the cost of diabetic care. Humalog is now $400. We can do this whenever we want and there’s nothing you can do about it. Suck it. Our official Twitter account is @LillyPadCo.”

The imposter accounts were removed quickly and it seems as though Musk is rapidly rethinking the Twitter Blue strategy. Lilly’s stock price will also recover, but the ensuing media storm is only just beginning. The situation has pushed the price of insulin into the spotlight – with public pressure and condemnation mounting. The top comments on Lilly’s apology are complaints about the price of insulin and accusations that the company puts profits ahead of patients.

Complaints about pricing are a constant battle in the world of big pharma – but it seems the fight has become significantly more dangerous and difficult now that social media trolls have realized just how quickly stock prices can be manipulated.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Related White Papers
Nitrosamines Risk Mitigation: The critical role of excipients and supplier qualification

| Contributed by DFE Pharma GmbH & Co. KG

Performance validation of ScatterX78 against NIST reference materials

| Contributed by Malvern Panalytical

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register